Search Results - "BLOEMENDAL, HAIKO J"

Effects of an Exercise Program in Colon Cancer Patients undergoing Chemotherapy by VAN VULPEN, JONNA K, VELTHUIS, MIRANDA J, STEINS BISSCHOP, CHARLOTTE N, TRAVIER, NOÉMIE, VAN DEN BUIJS, BRAM J W, BACKX, FRANK J G, LOS, MAARTJE, ERDKAMP, FRANS L G, BLOEMENDAL, HAIKO J, KOOPMAN, MIRIAM, DE ROOS, MARNIX A J, VERHAAR, MARLIES J, TEN BOKKEL-HUININK, DAAN, VAN DER WALL, ELSKEN, PEETERS, PETRA H M, MAY, ANNE M

“…PURPOSEFatigue is a common problem among colon cancer patients and typically increases during chemotherapy. Exercise during chemotherapy might have beneficial…”
Get full text

Four-year effects of exercise on fatigue and physical activity in patients with cancer by Witlox, Lenja, Hiensch, Anouk E, Velthuis, Miranda J, Steins Bisschop, Charlotte N, Los, Maartje, Erdkamp, Frans L G, Bloemendal, Haiko J, Verhaar, Marlies, Ten Bokkel Huinink, Daan, van der Wall, Elsken, Peeters, Petra H M, May, Anne M

“…In the earlier randomized controlled Physical Activity during Cancer Treatment (PACT) study, we found beneficial effects of an 18-week supervised exercise…”
Get full text

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis by Westdorp, Harm, Sweep, Mark W D, Gorris, Mark A J, Hoentjen, Frank, Boers-Sonderen, Marye J, van der Post, Rachel S, van den Heuvel, Michel M, Piet, Berber, Boleij, Annemarie, Bloemendal, Haiko J, de Vries, I Jolanda M

“…Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several cancer types. However, systemic activation of the immune system also…”
Get full text

The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs by Yildirim, Hilin, Widdershoven, Christiaan V, Aarts, Maureen Jb, Bex, Axel, Bloemendal, Haiko J, Bochove-Overgaauw, Deirdre M, Hamberg, Paul, Herbschleb, Karin H, van der Hulle, Tom, Lagerveld, Brunolf W, van Oijen, Martijn Gh, Oosting, Sjoukje F, van Thienen, Johannes V, van der Veldt, Astrid Am, Westgeest, Hans M, Zeijdner, Evelijn E, Aben, Katja Kh, van den Hurk, Corina, Zondervan, Patricia J, Bins, Adriaan D

“…Ongoing research in the field of both localized, locally advanced and metastatic renal cell carcinoma has resulted in the availability of multiple treatment…”
Get full text

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study by Peters, Niek A., Constantinides, Alexander, Ubink, Inge, van Kuik, Joyce, Bloemendal, Haiko J., van Dodewaard, Joyce M., Brink, Menno A., Schwartz, Thijs P., Lolkema, Martijn P.J.K., Lacle, Miangela M., Moons, Leon M., Geesing, Joost, van Grevenstein, Wilhelmina M.U., Roodhart, Jeanine M. L., Koopman, Miriam, Elias, Sjoerd G., Borel Rinkes, Inne H.M., Kranenburg, Onno

“…Background Mesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is associated with poor prognosis and therapy resistance. In this proof-of-concept…”
Get full text

Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision‐making? by Vrinzen, Cilla E. J., Bloemendal, Haiko J., Stuart, Esra, Makady, Amr, Agthoven, Michel, Koster, Mariska, Merkx, Matthias A. W., Hermens, Rosella P. M. G., Jeurissen, Patrick P. T.

“…Background Cancer rates and expenditures are increasing, resulting in debates on the exact value of this care. Perspectives on what exactly constitutes…”
Get full text

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids by van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M. L., Daenen, Laura G. M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., De Vos, Filip Y., Voest, Emile E.

“…Purpose Chemotherapy-resistance remains a major obstacle to effective anti-cancer treatment. We previously showed that platinum analogs cause the release of…”
Get full text

Pan-cancer whole-genome analyses of metastatic solid tumours by Priestley, Peter, Baber, Jonathan, Lolkema, Martijn P., Steeghs, Neeltje, de Bruijn, Ewart, Shale, Charles, Duyvesteyn, Korneel, Haidari, Susan, van Hoeck, Arne, Onstenk, Wendy, Roepman, Paul, Voda, Mircea, Bloemendal, Haiko J., Tjan-Heijnen, Vivianne C. G., van Herpen, Carla M. L., Labots, Mariette, Witteveen, Petronella O., Smit, Egbert F., Sleijfer, Stefan, Voest, Emile E., Cuppen, Edwin

“…Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A better understanding of the characteristics of late-stage cancer…”
Get full text

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies by Angus, Lindsay, Smid, Marcel, Wilting, Saskia M., van Riet, Job, Van Hoeck, Arne, Nguyen, Luan, Nik-Zainal, Serena, Steenbruggen, Tessa G., Tjan-Heijnen, Vivianne C. G., Labots, Mariette, van Riel, Johanna M. G. H., Bloemendal, Haiko J., Steeghs, Neeltje, Lolkema, Martijn P., Voest, Emile E., van de Werken, Harmen J. G., Jager, Agnes, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W. M.

“…The whole-genome sequencing of prospectively collected tissue biopsies from 442 patients with metastatic breast cancer reveals that, compared to primary breast…”
Get full text

Cancer treatment and decision making in individuals with intellectual disabilities: a scoping literature review by Boonman, Anne J, Cuypers, Maarten, Leusink, Geraline L, Naaldenberg, Jenneken, Bloemendal, Haiko J

“…Adults with intellectual disabilities face disparities in receipt of cancer-related care, which could contribute to an increase in the rate of cancer-related…”
Get full text

A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients by Heerma van Voss, Marise R, Notohardjo, Jessica, van Dodewaard-de Jong, Joyce, Bloemendal, Haiko J, ter Heine, Rob

“…Purpose Docetaxel is a cytotoxic drug used for first-line treatment of various malignancies. It has a narrow therapeutic index and shows wide interpatient…”
Get full text

Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial by Travier, Noémie, Velthuis, Miranda J, Steins Bisschop, Charlotte N, van den Buijs, Bram, Monninkhof, Evelyn M, Backx, Frank, Los, Maartje, Erdkamp, Frans, Bloemendal, Haiko J, Rodenhuis, Carla, de Roos, Marnix A J, Verhaar, Marlies, ten Bokkel Huinink, Daan, van der Wall, Elsken, Peeters, Petra H M, May, Anne M

“…Exercise started shortly after breast cancer diagnosis might prevent or diminish fatigue complaints. The Physical Activity during Cancer Treatment (PACT) study…”
Get full text

A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer by Vrinzen, Cilla E J, Delfgou, Linn, Stadhouders, Niek, Hermens, Rosella P M G, Merkx, Matthias A W, Bloemendal, Haiko J, Jeurissen, Patrick P T

“…Comorbidities can have major implications for cancer care, as they might impact the timing of cancer diagnosis, compromise optimal care, affect treatment…”
Get full text

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol by van Berge Henegouwen, Jade M, Zeverijn, Laurien J, Geurts, Birgit S, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, Huitema, Alwin D R, de Vos, Filip Y F, Grünberg, Katrien, Bloemendal, Haiko J, Verheul, Henk M W, Voest, Emile E, Gelderblom, Hans

“…Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance…”
Get full text

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases by Lange, Rogier, ter Heine, Rob, (FF) Knapp, Russ, de Klerk, John M.H, Bloemendal, Haiko J, Hendrikse, N. Harry

“…Abstract Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion electron emitting radioisotopes have been investigated…”
Get full text

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform by Zeverijn, Laurien J, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, van Roy, Anke A M G Pisters, Timmers, Lonneke, Ly Tran, T H, de Boer, Jolanda E, de Wit, Gijsbrecht F, Geurts, Birgit S, Gelderblom, Hans, Verheul, Henk M W, Blijlevens, Nicole, Wymenga, A N Machteld, Eskens, Ferry A L M, Smit, Egbert F, Bloemendal, Haiko J, Voest, Emile E

“…In Europe, an EAP is often considered an open-label extension study aiming to provide access to a medicine and generate additional safety data, whereas the…”
Get full text

Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study) by Overbeek, Joanneke K., Guchelaar, Niels A.D., Mohmaed Ali, Ma Ida, Ottevanger, Petronella B., Bloemendal, Haiko J., Koolen, Stijn L.W., Mathijssen, Ron H.J., Boere, Ingrid A., Hamberg, Paul, Huitema, Alwin D.R., Sonke, Gabe S., Opdam, Frans L., ter Heine, Rob, van Erp, Nielka P.

“…Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate,…”
Get full text

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer by Slootbeek, Peter H. J., Kloots, Iris S. H., Smits, Minke, van Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Ligtenberg, Marjolijn J. L., Grünberg, Katrien, Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven

“…Background Molecular tumour boards (MTB) optimally match oncological therapies to patients with genetic aberrations. Prostate cancer (PCa) is underrepresented…”
Get full text

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer by Slootbeek, Peter H. J., Duizer, Marleen L., Doelen, Maarten J., Kloots, Iris S. H., Kuppen, Malou C. P., Westgeest, Hans M., Uyl‐de Groot, Carin A., Pamidimarri Naga, Samhita, Ligtenberg, Marjolijn J. L., Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven

“…Platinum‐based chemotherapy is not standard of care for unselected or genetically selected metastatic castration‐resistant prostate cancer (mCRPC) patients. A…”
Get full text

Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review by Jong, Joyce M. van Dodewaard-de, Oprea-Lager, Daniela E, Hooft, Lotty, de Klerk, John M.H, Bloemendal, Haiko J, Verheul, Henk M.W, Hoekstra, Otto S, van den Eertwegh, Alfons J.M

“…Abstract Context The majority of patients with castration-resistant prostate cancer develop bone metastatic disease. It is often challenging to optimally…”
Get full text